---
layout: post
title: "M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms; International Council for Harmonisation; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:35:29 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-02106
original_published: 2023-02-01 00:00:00 +0000
significance: 8.00
---

# M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms; International Council for Harmonisation; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 01, 2023 00:00 UTC
**Document Number:** 2023-02106

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance describes the scientific and technical aspects of study design and data analysis to support bioequivalence (BE) assessment for orally administered immediate- release solid oral dosage forms, such as tablets, capsules, and granules/powders for oral suspension. The draft guidance is intended to provide globally harmonized scientific recommendations for conducting BE studies during both development and postapproval phases for these products.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/01/2023-02106/m13a-bioequivalence-for-immediate-release-solid-oral-dosage-forms-international-council-for)
- API: https://www.federalregister.gov/api/v1/documents/2023-02106

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
